SQZ Biotechnologies Company (SQZB)
Market Cap | 1.09M |
Revenue (ttm) | 18.61M |
Net Income (ttm) | -76.11M |
Shares Out | 29.49M |
EPS (ttm) | -2.61 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,238 |
Open | 0.0370 |
Previous Close | 0.0370 |
Day's Range | 0.0370 - 0.0370 |
52-Week Range | 0.0101 - 0.1479 |
Beta | 1.45 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About SQZB
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC... [Read more]
Financial Performance
In 2022, SQZB's revenue was $21.48 million, a decrease of -20.74% compared to the previous year's $27.10 million. Losses were -$79.46 million, 15.6% more than in 2021.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/o/h/press6-2302504.jpg)
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotec...
![](https://cdn.snapi.dev/images/v1/v/8/press2-2302427.jpg)
Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced the results for the proposals considered and voted upon by its shareholders at its s...
![](https://cdn.snapi.dev/images/v1/m/l/press13-2148346.jpg)
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial resul...
![](https://cdn.snapi.dev/images/v1/z/d/press6-2140022.jpg)
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatme...
![](https://cdn.snapi.dev/images/v1/h/k/press8-2018564.jpg)
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported second quarter 2023 financial results and recent p...
![](https://cdn.snapi.dev/images/v1/p/r/press2-1986185.jpg)
SQZ Biotechnologies Provides Update on Collaboration with Roche
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive s...
![](https://cdn.snapi.dev/images/v1/w/x/press11-1957350.jpg)
NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ)
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of S...
![](https://cdn.snapi.dev/images/v1/p/k/press4-1936603.jpg)
SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (the “Company” or “SQZ”), focused on unlocking the full potential of cell therapies, today announced that its Board of Direct...
![](https://cdn.snapi.dev/images/v1/w/i/press14-1883712.jpg)
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent po...
![](https://cdn.snapi.dev/images/v1/o/f/press16-1808774.jpg)
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirm...
![](https://cdn.snapi.dev/images/v1/5/e/press17-1808775.jpg)
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfo...
![](https://cdn.snapi.dev/images/v1/k/3/press6-1713603.jpg)
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ) today announced that on January 18, 2023, it received notice from the New York Stock Exchange (NYSE) indicating that the Company is...
![](https://cdn.snapi.dev/images/v1/r/n/press7-1694123.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ
NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such investors are advised to ...
![](https://cdn.snapi.dev/images/v1/x/b/press10-1679632.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SQZ Biotechnologies Company - SQZ
New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such invest...
![](https://cdn.snapi.dev/images/v1/b/t/press15-1666889.jpg)
Bronstein, Gewirtz & Grossman, LLC Announces SQZ Biotechnologies Company (SQZ) Investigation
NEW YORK , Dec. 7, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against SQZ Biotechnologies Company ("SQZ" or "the Company") (NYSE:...
![](https://cdn.snapi.dev/images/v1/l/9/press19-1663779.jpg)
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company's Enhan...
![](https://cdn.snapi.dev/images/v1/i/w/press18-1657620.jpg)
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ) today announced the strategic prioritization of its clinical portfolio to concentrate on the development of its second-generation e...
![](https://cdn.snapi.dev/images/v1/s/1/press9-1628831.jpg)
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.
![](https://cdn.snapi.dev/images/v1/g/u/press5-1566009.jpg)
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of...
![](https://cdn.snapi.dev/images/v1/r/r/press10-1539571.jpg)
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical data s...
![](https://cdn.snapi.dev/images/v1/t/q/conf17-1535414.jpg)
SQZ Biotechnologies to Present at Upcoming Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei,...
![](https://cdn.snapi.dev/images/v1/9/0/press8-1533252.jpg)
SQZ Biotechnologies Announces Leadership Transition
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernst...
![](https://cdn.snapi.dev/images/v1/r/r/press18-1489133.jpg)
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2022 financi...
![](https://cdn.snapi.dev/images/v1/7/6/press10-1449574.jpg)
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of...